Spot-fading and whitening composition comprising sulfated schizophyllan and use thereof

Abstract

A spot-fading and whitening composition comprising sulfated schizophyllan and use thereof. The composition comprises sulfated schizophyllan, a compound amino acid, α-arbutin, and an ascorbic acid compound. The composition has multiple effects of unclogging blood vessels, improving microcirculation, promoting skin metabolism, reducing melanin production, fading spots, and whitening, tenderizing, moisturizing, and nourishing the skin.

Description

A spot-lightening and whitening composition containing sulfated schizophyllan and its application

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This disclosure claims priority to Chinese patent application No. 202311690556.3 filed with the State Intellectual Property Office of China on December 8, 2023, entitled “A freckle-removing and whitening composition containing sulfated schizophyllan and its application,” the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present disclosure belongs to the technical field of cosmetics and relates to a spot-lightening and whitening composition containing sulfated schizophyllan and an application thereof. Background Art

[0004] Environmental pollution, UV radiation, and changes in the internal microenvironment can cause changes in the fibrin in facial microcirculation, blocking blood vessels and leading to qi stagnation and blood stasis, preventing skin cells from receiving proper nutrients. This ultimately leads to pigmentation, dull skin, and nutrient deficiency. With aging, skin metabolism declines, increasing the risk of yellowing and freckles. This makes it essential to promote skin metabolism to address the skin problems associated with aging. Promoting blood circulation in the microvasculature accelerates skin cell metabolism, restoring the elasticity of rigid blood vessel walls. This allows nutrients, water, and oxygen to fully reach elastic and collagen fibers, maintaining their normal function, revitalizing cells, and restoring skin's radiance and elasticity. In other words, beautiful skin lies in the health of blood vessels. Many European beauty research institutions have begun using substances such as peptides and hirudin to dilate skin capillaries and promote blood circulation, thereby reducing blood viscosity and improving microcirculation, resulting in cosmetic benefits.

[0005] Sulfated polysaccharide derivatives, represented by heparin, possess prominent anticoagulant and thrombolytic properties. This is attributed to the specific interaction of negatively charged groups within the polysaccharide with coagulation factors in the blood, thereby inhibiting thrombin activity. Anticoagulant polysaccharides added to cosmetics are absorbed through the skin, entering the subcutaneous microvasculature, where they bind to coagulation factors, reducing fibrin levels in the vessels, unclogging blood vessels, and accelerating the entry of nutrients into the skin through microcirculation, thereby improving skin metabolism. Sulfated schizophyllan, due to its excellent anticoagulant and moisturizing properties, can be combined with other active ingredients for use in cosmetics.

[0006] Summary of the Invention

[0007] In view of the deficiencies in the prior art, the present invention aims to provide a spot-lightening and whitening composition containing sulfated Schizophyllan and its application.

[0008] To achieve this disclosure purpose, the present disclosure adopts the following technical solutions:

[0009] In a first aspect, the present disclosure provides a freckle-lightening and whitening composition containing sulfated Schizophyllan, wherein the freckle-lightening and whitening composition containing sulfated Schizophyllan comprises sulfated Schizophyllan, complex amino acids, α-arbutin, and ascorbic acid complex.

[0010] Sulfated schizophyllan is derived from the sulfated schizophyllan and is a naturally derived substance with excellent properties such as moisturizing activity and anticoagulant activity, thereby achieving multiple effects such as lightening, moisturizing, and whitening the skin. The composition of the composite amino acids is equivalent to or similar to the ratio of the amino acid components in the stratum corneum of the skin, providing nutrition to the skin cells, thereby achieving a long-term moisturizing effect, while promoting the synthesis of collagen and elastin, and providing nutrients to the cells. The ratio of α-arbutin and ascorbic acid can inhibit the activity of tyrosinase, effectively preventing the synthesis of melanin, and its strong antioxidant properties can also effectively remove free radicals, thereby achieving a whitening effect. The present invention compounded the composite of sulfated schizophyllan, composite amino acids, α-arbutin, and ascorbic acid to prepare a facial cream, utilizing the anticoagulant activity and moisturizing properties of sulfated schizophyllan, combined with the arbutin and ascorbic acid composite to synergistically enhance the effect, dredge blood vessels, improve microcirculation, promote skin metabolism, and reduce melanin production, thereby achieving multiple effects of lightening, whitening, rejuvenating, moisturizing, and nourishing.

[0011] Preferably, the freckle-lightening and whitening composition containing sulfated Schizophyllan comprises, by mass, 0.1-5 parts of sulfated Schizophyllan, 4.5-10 parts of complex amino acids, and 0.2-5 parts of α-arbutin and ascorbic acid complex.

[0012] When compounded in the above specific ratio, the composition has better spot-lightening, whitening and moisturizing effects.

[0013] The mass fraction of sulfated schizophyllan can be selected from 0.1 parts, 0.2 parts, 0.4 parts, 0.6 parts, 0.8 parts, 1 part, 1.2 parts, 1.4 parts, 1.6 parts, 1.8 parts, 2 parts, 2.2 parts, 2.4 parts, 2.6 parts, 2.8 parts, 3 parts, 3.2 parts, 3.4 parts, 3.6 parts, 3.8 parts, 4 parts, 4.2 parts, 4.4 parts, 4.6 parts, 4.8 parts, 5 parts, etc. The mass fraction of the complex amino acid can be selected from 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, The mass fractions of the α-arbutin and ascorbic acid complex can be selected from 0.2 parts, 0.4 parts, 0.6 parts, 0.8 parts, 1 part, 1.2 parts, 1.4 parts, 1.6 parts, 1.8 parts, 2 parts, 2.2 parts, 2.4 parts, 2.6 parts, 2.8 parts, 3 parts, 3.2 parts, 3.4 parts, 3.6 parts, 3.8 parts, 4 parts, 4.2 parts, 4.4 parts, 4.6 parts, 4.8 parts, 5 parts, etc. Other specific values ​​within the above numerical range can be selected, which will not be repeated here.

[0014] Preferably, the complex amino acids include lysine, leucine, arginine and aspartic acid.

[0015] In a second aspect, the present disclosure provides a use of the spot-lightening and whitening composition containing sulfated Schizophyllan according to the first aspect in the preparation of cosmetics.

[0016] Preferably, the cosmetic comprises lotion, facial mask, facial cream or essence cream.

[0017] Preferably, the mass fraction of the freckle-lightening and whitening composition containing sulfated schizophyllan in the cosmetic is 3-6 parts, for example, 3 parts, 3.2 parts, 3.4 parts, 3.6 parts, 3.8 parts, 4 parts, 4.2 parts, 4.4 parts, 4.6 parts, 4.8 parts, 5 parts, 5.2 parts, 5.4 parts, 5.6 parts, 5.8 parts, 6 parts, etc. Other specific point values ​​within the above numerical range can be selected, and they will not be repeated here.

[0018] In a third aspect, the present disclosure provides a freckle-lightening and whitening facial cream containing sulfated Schizophyllan, wherein the freckle-lightening and whitening facial cream containing sulfated Schizophyllan comprises the freckle-lightening and whitening composition containing sulfated Schizophyllan described in the first aspect, a moisturizer, a thickener, a preservative, and water.

[0019] Preferably, the freckle-lightening and whitening cream containing sulfated Schizophyllan comprises, by mass, 3-6 parts of the freckle-lightening and whitening composition containing sulfated Schizophyllan described in the first aspect, 7-12 parts of a moisturizer, 0.1-0.4 parts of a thickener, 2-5 parts of an emulsifier, and water.

[0020] The mass fraction of the freckle-lightening and whitening composition containing sulfated schizophyllan can be selected from 3 parts, 3.2 parts, 3.4 parts, 3.6 parts, 3.8 parts, 4 parts, 4.2 parts, 4.4 parts, 4.6 parts, 4.8 parts, 5 parts, 5.2 parts, 5.4 parts, 5.6 parts, 5.8 parts, 6 parts, etc., and the mass fraction of the moisturizer can be selected from 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, The mass fraction of the thickener can be selected from 0.1 parts, 0.15 parts, 0.2 parts, 0.25 parts, 0.3 parts, 0.35 parts, 0.4 parts, etc. The mass fraction of the emulsifier can be selected from 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, etc. Other specific point values ​​within the above numerical range can be selected, so they will not be repeated here.

[0021] Preferably, the emulsifier comprises glyceryl stearate and / or PEG-100 stearate.

[0022] Preferably, the moisturizing agent includes any one of 1,3-butylene glycol, glycerin or allantoin, or a combination of at least two thereof.

[0023] Preferably, the thickening agent comprises carbomer and / or xanthan gum.

[0024] Preferably, the spot-lightening and whitening facial cream containing sulfated Schizophyllan further comprises any one of a preservative, a emollient, a pH regulator or a chelating agent, or a combination of at least two thereof.

[0025] Preferably, the preservative comprises phenoxyethanol and ethylhexylglycerin complex.

[0026] Preferably, the emollient comprises any one of isopropyl palmitate, caprylic capric triglyceride, squalane, cetearyl alcohol, behenyl alcohol, dimethicone or isononyl isononanoate, or a combination of at least two thereof.

[0027] Preferably, the pH adjuster comprises aminomethyl propanol.

[0028] Preferably, the chelating agent comprises disodium EDTA.

[0029] In a fourth aspect, the present disclosure provides a method for preparing a spot-lightening and whitening facial cream containing sulfated Schizophyllan, the preparation method comprising: mixing a moisturizer, an emulsifier, a thickener, and water, and then mixing the mixture with the spot-lightening and whitening composition containing sulfated Schizophyllan.

[0030] Preferably, the temperature at which the moisturizer, emulsifier, thickener and water are mixed is 80-85°C, for example, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, etc. Other specific values ​​within the above numerical range can be selected and will not be described here one by one.

[0031] Preferably, the temperature for mixing with the freckle-lightening and whitening composition containing sulfated schizophyllan is 40-43°C, such as 41°C, 42°C, 43°C, etc. Other specific values ​​within the above numerical range can be selected and will not be described here one by one.

[0032] Preferably, the moisturizer, emulsifier, thickener and water are mixed together with a chelating agent and / or an emollient.

[0033] Preferably, the spot-lightening and whitening composition containing sulfated Schizophyllan is mixed with a pH regulator and / or a preservative.

[0034] Compared with the prior art, the present disclosure has the following beneficial effects:

[0035] Sulfated schizophyllan is derived from the sulfated schizophyllan and is a naturally derived substance with excellent properties such as moisturizing activity and anticoagulant activity, thereby achieving multiple effects such as lightening, moisturizing, and whitening the skin. The composition of the composite amino acids is equivalent to or similar to the ratio of the amino acid components in the stratum corneum of the skin, providing nutrition to the skin cells, thereby achieving a long-term moisturizing effect, while promoting the synthesis of collagen and elastin, and providing nutrients to the cells. The ratio of α-arbutin and ascorbic acid can inhibit the activity of tyrosinase, effectively preventing the synthesis of melanin, and its strong antioxidant properties can also effectively remove free radicals, thereby achieving a whitening effect. The present invention compounded a complex of sulfated schizophyllan, composite amino acids, α-arbutin, and ascorbic acid to prepare a facial cream, utilizing the anticoagulant activity and moisturizing properties of sulfated schizophyllan, combined with the arbutin and ascorbic acid complex to synergistically enhance the effect, dredge blood vessels, improve microcirculation, promote skin metabolism, and reduce melanin production, thereby achieving multiple effects of lightening, whitening, rejuvenating, moisturizing and nourishing. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 shows the effects of Schizophyllan on APTT, TT, and PT.

[0037] FIG2 shows the effect of the sulfated Schizophyllan described in Preparation Example 1 on APTT, TT, and PT. DETAILED DESCRIPTION

[0038] The technical solution of the present disclosure is further described below through specific implementation methods. Those skilled in the art should understand that the embodiments are only used to help understand the present disclosure and should not be regarded as specific limitations of the present disclosure.

[0039] The sources of the functional ingredients contained in the products involved in the following embodiments, comparative examples, application examples, and comparative application examples are as follows (only the functional ingredients are reflected, and the necessary auxiliary ingredients contained in other commercially available raw materials are not repeated):

[0040] Schizophyllan was purchased from Emerald Switzerland under the trade name Schizophyllan;

[0041] Carbomer was purchased from Zhaoheng Company under the trade name of Carbomer 940 thickener;

[0042] Xanthan gum was purchased from Noran Corporation under the trade name Cosphaderm X34;

[0043] Allantoin was purchased from Aoxue Company under the trade name of Allantoin;

[0044] PEG-100 stearate was purchased from Yujin Company under the trade name Arlacel 170;

[0045] Dimethyl silicone oil was purchased from SiCare 201, a product of SiCare Corporation.

[0046] Preparation Example 1

[0047] This preparation example provides a sulfated schizophyllan, and its preparation method is as follows: take 1g of dried schizophyllan, put it into a screw-mouth conical flask, add 150mL of DMF, and soak it in a dry environment for 12h. Add 4g of sulfur trioxide pyridine, react in a water bath at 70°C for 3h, and stir at a rate of 700rpm. After the reaction is completed, add 200mL of pre-cooled distilled water, adjust the pH value of the solution to 7.5 with 2mol / L NaOH, add 95% ethanol to a final ethanol concentration of 75% for alcohol precipitation, and redissolve the polysaccharide with distilled water. After dialyzing for 72h using an ultrafiltration membrane with a molecular weight cutoff of 30kD, concentrate under reduced pressure at 50°C, and freeze-dry to obtain sulfated schizophyllan S-SPG.

[0048] Example 1

[0049] This embodiment provides a freckle-lightening and whitening composition containing sulfated schizophyllan, which comprises, in parts by mass, 5 parts of sulfated schizophyllan described in Preparation Example 1, 10 parts of complex amino acids, and 1 part of an α-arbutin and ascorbic acid complex, wherein the mass ratio of lysine, leucine, arginine, and aspartic acid in the complex amino acids is 4:7:4:8, and the mass ratio of α-arbutin and ascorbic acid in the α-arbutin and ascorbic acid complex is 5:4.

[0050] The preparation method comprises the following steps: mixing sulfated schizophyllan, complex amino acids, alpha-arbutin and ascorbic acid complex to obtain the product.

[0051] Example 2

[0052] This embodiment provides a freckle-lightening and whitening composition containing sulfated schizophyllan, which comprises, in parts by mass, 3 parts of sulfated schizophyllan described in Preparation Example 1, 8 parts of complex amino acids, and 3 parts of an α-arbutin and ascorbic acid complex, wherein the mass ratio of lysine, leucine, arginine, and aspartic acid in the complex amino acids is 4:7:4:8, and the mass ratio of α-arbutin and ascorbic acid in the α-arbutin and ascorbic acid complex is 5:4.

[0053] The preparation method is as in Example 1.

[0054] Example 3

[0055] This embodiment provides a freckle-lightening and whitening composition containing sulfated schizophyllan, which comprises, in parts by mass, 1 part of sulfated schizophyllan described in Preparation Example 1, 4.5 parts of complex amino acids, and 5 parts of an α-arbutin and ascorbic acid complex, wherein the mass ratio of lysine, leucine, arginine, and aspartic acid in the complex amino acids is 4:7:4:8, and the mass ratio of α-arbutin and ascorbic acid in the α-arbutin and ascorbic acid complex is 5:4.

[0056] The preparation method is as in Example 1.

[0057] Comparative Example 1

[0058] This comparative example provides a whitening and freckle-removing composition containing sulfated schizophyllan, which differs from Example 1 only in that it does not contain sulfated schizophyllan, and its reduced mass is proportionally distributed to the mass of the complex amino acid, α-arbutin, and ascorbic acid complex, while the other ingredients and contents remain unchanged.

[0059] The preparation method is as in Example 1.

[0060] Comparative Example 2

[0061] This comparative example provides a whitening and freckle-removing composition containing sulfated schizophyllan, which differs from Example 1 only in that it does not contain complex amino acids, and its reduced mass is proportionally distributed to the mass of the sulfated schizophyllan, α-arbutin, and ascorbic acid complex, while the other ingredients and contents remain unchanged.

[0062] The preparation method is as in Example 1.

[0063] Comparative Example 3

[0064] This comparative example provides a whitening and freckle-removing composition containing sulfated schizophyllan, which differs from Example 1 only in that it does not contain α-arbutin and ascorbic acid complex, and the reduced mass thereof is proportionally distributed to the mass of sulfated schizophyllan and complex amino acids, while the other ingredients and contents remain unchanged.

[0065] The preparation method is as in Example 1.

[0066] Comparative Example 4

[0067] This comparative example provides a spot-lightening and whitening composition containing sulfated Schizophyllan, which differs from Example 1 only in that an equal amount of sulfated Schizophyllan is replaced by Schizophyllan, and other ingredients and contents remain unchanged.

[0068] The preparation method is as in Example 1.

[0069] Application Example 1

[0070] This application example provides a spot-lightening and whitening facial cream containing sulfated schizophyllan, the formula of which is as follows:

[0071] Its preparation method is:

[0072] The moisturizer, emulsifier, thickener, emollient, chelating agent and water are mixed at 80° C., and then mixed with the spot-lightening and whitening composition containing sulfated schizophyllan, pH regulator and preservative at 42° C. to obtain the product.

[0073] Application Example 2

[0074] This application example provides a spot-lightening and whitening facial cream containing sulfated schizophyllan, the formula of which is as follows:

[0075] Its preparation method is:

[0076] The moisturizer, emulsifier, thickener, emollient, chelating agent and water are mixed at 85° C., and then mixed with the spot-lightening and whitening composition containing sulfated schizophyllan, pH regulator and preservative at 43° C. to obtain the product.

[0077] Application Example 3

[0078] Its preparation method is:

[0079] The moisturizer, emulsifier, thickener, emollient, chelating agent and water are mixed at 80° C., and then mixed with the spot-lightening and whitening composition containing sulfated schizophyllan, pH regulator and preservative at 40° C. to obtain the product.

[0080] Comparative Application Examples 1-4

[0081] This comparative application example provides a whitening and freckle-lightening cream containing sulfated Schizophyllan, which differs from Example 1 only in that the whitening and freckle-lightening composition containing sulfated Schizophyllan described in Example 1 is replaced by the compositions described in Comparative Examples 1-4 in equal amounts, and other ingredients and contents remain unchanged.

[0082] The preparation method refers to Application Example 1.

[0083] Test Example 1

[0084] Determination of anticoagulant activity of sulfated Schizophyllan

[0085] The sulfated schizophyllan and schizophyllan described in Preparation Example 1 were subjected to the determination of the thromboplastin time (APTT), thrombin time (TT), and prothrombin time (PT).

[0086] Test Method: Cardiac blood from healthy adult rabbits was added to an 8% sodium citrate solution at a ratio of 1:9 (8% sodium citrate): rabbit blood. The mixture was mixed thoroughly and centrifuged at 3000 rpm for 15 minutes to obtain plasma. 450 μL of plasma was placed in a glass test tube, 50 μL of samples of varying concentrations were added, and the mixture was mixed thoroughly. 50 μL of the mixed plasma was incubated with 50 μL of APTT reagent for 3 minutes. 50 μL of 0.025 mol / L CaCl₂ solution was added and the coagulometer automatically started the timer to determine the AATP time. 100 μL of the mixed plasma was incubated for 2 minutes. 100 μL of the TT reagent was added and the coagulometer automatically started the timer to determine the TT time. 50 μL of the mixed plasma was incubated for 2 minutes. 100 μL of the PT reagent was added and the coagulometer automatically started the timer to determine the PT time. Positive controls were 0.01 mg / mL and 0.025 mg / mL heparin sodium, and the negative control was 0.9% saline.

[0087] Test Results: The results are shown in Figures 1 and 2. The upper limits of detection for APTT, TT, and PT in this test were 190 s, 90 s, and 90 s, respectively. Values ​​exceeding these limits are not displayed in the bar graphs. Figure 1 shows that Schizophyllan did not prolong either APTT or PT at concentrations between 0.5 and 4 mg / mL, while slightly prolonging TT. However, increasing concentration had no effect on TT duration. Figure 2 shows that S-SPG did not prolong PT at concentrations between 0.01 and 0.2 mg / mL, but significantly prolonged both APTT and TT. At a concentration of 0.15 mg / mL, TT began to exceed 90 s, and at a concentration of 0.2 mg / mL, APTT reached the level of the positive control. Overall, compared to Schizophyllan, sulfated Schizophyllan exhibited stronger anticoagulant activity, and its activity was directly proportional to concentration. Sulfated Schizophyllan significantly prolongs the APTT and TT, but lacks prolongation of the PT, indicating that it exerts its anticoagulant activity through the endogenous coagulation pathway. This is similar to the coagulation pathway of sodium heparin and other sulfated polysaccharides. Based on its excellent anticoagulant activity in the APTT and TT tests, it could be used in cosmetics to unclog blood vessels, promote microcirculation, and accelerate skin metabolism.

[0088] Test Example 2

[0089] Moisturizing efficacy test

[0090] 70 volunteers uniformly cleaned the curved side of their left and right forearms, and gently dried them with a paper towel. A total of 10 people in each sample group participated in the test. Each person in each sample group marked 3 areas of 4cm×4cm as test areas, with at least 2cm between each area. The test results were statistically averaged. Appropriate amounts of equal amounts of Application Examples 1-3 and Comparative Application Examples 1-4 samples were applied to the test areas. Data collection of the subjects was arranged before using the samples and 2 hours and 4 hours after use. Skin parameters were collected each time using a skin testing instrument (Corneometer CM825), and the growth rate (%) of the moisture content of the skin stratum corneum was calculated. Growth rate = (moisture content after n hours of use - moisture content before use) / moisture content before use. The results are shown in Table 1.

[0091] Table 1

[0092] It can be seen from the data in Table 1 that the facial cream disclosed in the present invention has a good moisturizing effect, and the sulfated schizophyllan, complex amino acids, α-arbutin, and ascorbic acid complex have a certain synergistic effect in improving the moisturizing effect.

[0093] Test Example 3

[0094] Spot-lightening efficacy test

[0095] The skin improvement satisfaction ratings for the creams prepared using Examples 1-3 and Comparative Examples 1-4 were evaluated. The specific method was as follows: 70 female volunteers aged 25 to 45 were selected and divided into 7 groups. The creams prepared using Examples 1-3 and Comparative Examples 1-4 were applied to the facial skin twice a day for 12 weeks. The participants were then asked to rate the skin care products based on their skin improvement. The scoring criteria are shown in Table 2, and the results are shown in Table 3.

[0096] Table 2

[0097] Table 3

[0098] It can be seen from the data in Table 3 that the facial cream disclosed in the present invention has a good whitening and spot-removing effect, and the sulfated Schizophyllan, complex amino acids, α-arbutin, and ascorbic acid complex have a certain synergistic effect in improving the whitening and spot-removing effect, and the effect of sulfated Schizophyllan is better than that of Schizophyllan.

[0099] Test Example 4

[0100] Whitening efficacy test

[0101] Test samples: Application Examples 1-3 and Comparative Application Examples 1-4

[0102] 1.1 Sample preparation

[0103] Prepare the sample at a ratio of 0.45 mg sample to 1 mL serum-free culture medium;

[0104] 1.2 Cell culture

[0105] Mouse B16 melanoma cells were grown to confluency, digested with trypsin-EDTA for 5 minutes, and dispersed by pipetting. The cell suspension was aspirated into a centrifuge tube and centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded and culture medium was added to prepare a cell suspension. The cell suspension was diluted with culture medium to a certain concentration. B16 cells in the logarithmic growth phase were seeded in a 96-well plate at a cell density of 7×10 4 CFU / mL, 100 μL per well, mark the top cover of the cell plate after plating, and culture in an incubator for 24 hours.

[0106] After 24 hours of culture, carefully remove the supernatant from the cell plate using a pipette and divide the plates into blank, positive control, and sample groups. Add the prepared sample to the sample group, culture medium containing α-arbutin to the positive control, and serum-free medium to the blank group. Add 100 μL / well, with four replicates for each concentration. After addition, incubate the plates in an incubator for 72 hours.

[0107] 1.3 Determination of intracellular tyrosinase inhibition rate

[0108] After incubation for 72 hours, discard the supernatant and add 150 μL of 1% Triton X-100 solution to each well of the cell plate. Immediately freeze the plate at -80°C for 30 minutes and then thaw at room temperature to completely disrupt the cells. After prewarming at 37°C for 5 minutes, add 60 μL of 0.5% L-DOPA solution and incubate at 37°C for 2 hours. Measure the absorbance (OD) at 490 nm using a microplate reader. Calculate the tyrosinase activity inhibition rate.

[0109] Tyrosinase activity inhibition rate (%) = (1-average absorbance value of sample / average absorbance value of blank) × 100%.

[0110] Table 4

[0111] It can be seen from the data in Table 4 that the facial cream disclosed in the present invention has a good whitening effect, and the sulfated Schizophyllan, complex amino acids, α-arbutin, and ascorbic acid complex have a certain synergistic effect in improving the whitening effect, and the effect of sulfated Schizophyllan is better than that of Schizophyllan.

[0112] Test Example 5

[0113] Security Testing

[0114] The creams from Application Examples 1-3 and Comparative Application Examples 1-4 were tested for skin irritation. Seventy subjects were selected and patch test tape containing 0.03 mL of sample was applied to the normal skin of the subjects' left and right forearms. Within half an hour after removing the patch, the test was performed six times according to the CTFA guidelines (1981). Six days after the patch was removed, an additional test was performed to observe delayed reactions. The evaluation criteria are shown in Table 5, and the results are shown in Table 6.

[0115] Table 5

[0116] Table 6

[0117] From the above data results, it can be seen that the composition involved in the present disclosure and the cosmetics containing the same are non-irritating to the skin, have no positive reaction, and have a mild and non-irritating effect.

[0118] The applicant declares that while the present disclosure uses the above-mentioned embodiments to illustrate a freckle-lightening and whitening composition containing sulfated schizophyllan and its applications, the present disclosure is not limited to the above-mentioned embodiments, and does not necessarily rely on the above-mentioned embodiments for implementation. Those skilled in the art should understand that any improvements to the present disclosure, equivalent replacements for the raw materials of the disclosed products, addition of auxiliary ingredients, and selection of specific methods, etc., fall within the scope of protection and disclosure of the present disclosure.

[0119] The preferred embodiments of the present disclosure are described in detail above. However, the present disclosure is not limited to the specific details of the above embodiments. Within the technical concept of the present disclosure, various simple modifications can be made to the technical solutions of the present disclosure, and these simple modifications all fall within the scope of protection of the present disclosure.

[0120] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any appropriate manner without contradiction. In order to avoid unnecessary repetition, the present disclosure will not further describe various possible combinations. Industrial Applicability

[0121] Sulfated schizophyllan is derived from the sulfated schizophyllan and is a naturally derived substance with excellent properties such as moisturizing activity and anticoagulant activity, thereby achieving multiple effects such as lightening, moisturizing, and whitening the skin. The composition of the composite amino acids is equivalent to or similar to the ratio of the amino acid components in the stratum corneum of the skin, providing nutrition to the skin cells, thereby achieving a long-term moisturizing effect, while promoting the synthesis of collagen and elastin, and providing nutrients to the cells. The ratio of α-arbutin and ascorbic acid can inhibit the activity of tyrosinase, effectively preventing the synthesis of melanin, and its strong antioxidant properties can also effectively remove free radicals, thereby achieving a whitening effect. The present invention compounded a complex of sulfated schizophyllan, composite amino acids, α-arbutin, and ascorbic acid to prepare a facial cream, utilizing the anticoagulant activity and moisturizing properties of sulfated schizophyllan, combined with the arbutin and ascorbic acid complex to synergistically enhance the effect, dredge blood vessels, improve microcirculation, promote skin metabolism, and reduce melanin production, thereby achieving multiple effects of lightening, whitening, rejuvenating, moisturizing and nourishing.

[0122] Furthermore, it is understood that the freckle-lightening and whitening composition containing sulfated Schizophyllan and its applications provided by the embodiments of the present disclosure are reproducible and can be used in a variety of industrial applications. For example, the freckle-lightening and whitening composition containing sulfated Schizophyllan and its applications provided by the embodiments of the present disclosure can be used in the field of cosmetic technology.

Claims

1. A spot-lightening and whitening composition containing sulfated schizophyllan, characterized in that: The spot-lightening and whitening composition containing sulfated Schizophyllan comprises sulfated Schizophyllan, complex amino acids, α-arbutin and ascorbic acid complex.

2. The spot-lightening and whitening composition containing sulfated Schizophyllan according to claim 1, characterized in that: The freckle-lightening and whitening composition containing sulfated Schizophyllan comprises, by weight, 0.1-5 parts of sulfated Schizophyllan, 4.5-10 parts of complex amino acids, and 0.2-5 parts of α-arbutin and ascorbic acid complex; Preferably, the complex amino acids include lysine, leucine, arginine and aspartic acid.

3. Use of the spot-lightening and whitening composition containing sulfated Schizophyllan according to claim 1 or 2 in the preparation of cosmetics.

4. The use according to claim 3, characterized in that: The cosmetics include lotion, facial mask, facial cream or essence cream.

5. The cosmetic according to claim 3 or 4, characterized in that: The mass proportion of the spot-lightening and whitening composition containing sulfated Schizophyllan in the cosmetic is 3-6 parts.

6. A spot-lightening and whitening facial cream containing sulfated schizophyllan, characterized in that: The freckle-lightening and whitening facial cream containing sulfated Schizophyllan comprises the freckle-lightening and whitening composition containing sulfated Schizophyllan according to claim 1, a moisturizer, a thickener, a preservative and water.

7. The spot-lightening and whitening facial cream containing sulfated Schizophyllan according to claim 6, characterized in that: The freckle-lightening and whitening facial cream containing sulfated Schizophyllan comprises, by weight, 3-6 parts of the freckle-lightening and whitening composition containing sulfated Schizophyllan according to claim 1, 7-12 parts of a moisturizer, 0.1-0.4 parts of a thickener, 2-5 parts of an emulsifier, and water; Preferably, the emulsifier comprises glyceryl stearate and / or PEG-100 stearate; Preferably, the moisturizing agent comprises any one or a combination of at least two of 1,3-butylene glycol, glycerol or allantoin; Preferably, the thickener comprises carbomer and / or xanthan gum.

8. The spot-lightening and whitening facial cream containing sulfated Schizophyllan according to claim 6 or 7, characterized in that: The spot-lightening and whitening facial cream containing sulfated Schizophyllan also includes any one of a preservative, a emollient, a pH regulator or a chelating agent, or a combination of at least two thereof; Preferably, the preservative comprises a complex of phenoxyethanol and ethylhexylglycerin; Preferably, the emollient comprises any one or a combination of at least two of isopropyl palmitate, caprylic capric triglyceride, squalane, cetearyl alcohol, isopropyl palmitate, behenyl alcohol, dimethicone or isononyl isononanoate; Preferably, the pH adjuster comprises aminomethyl propanol; Preferably, the chelating agent comprises disodium EDTA.

9. The method for preparing a spot-lightening and whitening facial cream containing sulfated Schizophyllan according to any one of claims 6 to 8, characterized in that: The preparation method comprises: mixing a moisturizer, an emulsifier, a thickener and water, and then mixing the mixture with the spot-lightening and whitening composition containing sulfated schizophyllan to obtain the product.

10. The method for preparing the spot-lightening and whitening facial cream containing sulfated Schizophyllan according to claim 9, characterized in that: The temperature at which the moisturizer, emulsifier, thickener and water are mixed is 80-85°C; Preferably, the temperature of mixing the spot-lightening and whitening composition containing sulfated schizophyllan is 40-43°C; Preferably, the moisturizer, emulsifier, thickener and water are mixed with a chelating agent and / or an emollient; Preferably, the spot-lightening and whitening composition containing sulfated Schizophyllan is mixed with a pH regulator and / or a preservative.

Images